Seeking Alpha

Ganetespib "ripe for partnership": Roth

  • Roth Capital is out with some positive commentary on Synta Pharmaceuticals (SNTA +10.5%) following the announcement of new clinical trials for ganetespib
  • "We continue to look towards interim analysis from the GALAXY-2 trial in NSCLC in H2 and top-line data in H1 2015," analyst Joseph Pantginis says, adding that "as the ganetespib profile continues to broaden, [he] continues to believe that the drug is ripe for a partnership in the relative near term."
  • Price target is $27, representing upside of 295% from Thursday's close.
Comments (1)
  • TruffelPig
    , contributor
    Comments (4085) | Send Message
    The recent clinical data were not so hip I'd say.....
    10 Jan, 08:01 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector